Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypogonadism, Hypogonadotropic Clear all
Terminated No phase listed Observational

Psychological Outcomes in Isolated GnRH Deficiency

NCT02356172
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 200 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 2, 2026, 3:54 AM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 2, 2026, 3:54 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional Results available

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Low Testosterone
Interventions
Naloxone
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuropeptides in Human Reproduction

NCT01952782
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121, Naloxone, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional

Kisspeptin in the Evaluation of Delayed Puberty

NCT01438034
View directory record Official record
Conditions
Delayed Puberty, Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 2, 2026, 3:54 AM EDT
Active, not recruiting No phase listed Observational

Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing

NCT04733274
View directory record Official record
Conditions
Hypogonadism, Hypogonadotropic, Kallmann Syndrome
Interventions
Not listed
Lead sponsor
Boston College
Other
Eligibility
18 Years to 70 Years
Enrollment
227 participants
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 2, 2026, 3:54 AM EDT
Recruiting No phase listed Observational

Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

NCT06357442
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01534208
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

A 6 Month Safety Extension Study of MBGS205

NCT02908074
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 2, 2026, 3:54 AM EDT
Not listed Phase 2 Interventional

Pulsatile GnRH in Anovulatory Infertility

NCT00383656
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions
GnRH, Pump
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 2, 2026, 3:54 AM EDT
Not listed Not applicable Interventional

Baselines in Reproductive Disorders

NCT00456274
View directory record Official record
Conditions
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions
Frequent baseline blood sampling
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650
View directory record Official record
Conditions
Hypogonadism
Interventions
Nasobol®, Androderm® (Positive Control)
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

NCT04648969
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 1 Interventional

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 2, 2026, 3:54 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders

NCT01165619
View directory record Official record
Conditions
Idiopathic Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 2, 2026, 3:54 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 2, 2026, 3:54 AM EDT